Key insights
- Zealand Pharma's stock experienced a significant decline following the conclusion of the American Diabetes Association's Scientific Sessions. While Phase 2 data for petrelintide showed clinically meaningful weight reduction, it largely confirmed prior expectations and lacked differentiation compared to competitors like Eli Lilly's eloralintide. A prior analyst downgrade to Neutral from Overweight by Cantor Fitzgerald, citing limited differentiation and a potentially third-to-market position, exacerbated the sell-off. Deutsche Bank maintained a Hold rating, reflecting pipeline challenges. This news suggests potential headwinds for companies
Investing.com -- Zealand Pharma stock plunged -26.9% to trade at DKK 238.7 during today’s session, as the final day of the American Diabetes Association’s 2026 Scientific Sessions in New Orleans marked the end of a major near-term catalyst for the Danish biotech.
The company had been scheduled to present Phase 2 ZUPREME-1 data on petrelintide, its amylin analog developed in collaboration with Roche, as part of the ADA Official Press Program at the conference running June 5–8.
Results from the 42-week trial showed that participants achieved clinically meaningful reductions in body weight compared to placebo, with treatment also associated with improvements in cardiometabolic risk factors and a tolerability profile generally similar to placebo.
However, the data largely confirmed what had already been telegraphed to the market, and investor enthusiasm evaporated as the event concluded.
A significant overhang came from a high-profile analyst downgrade issued just days before the ADA conference ended. Cantor Fitzgerald cut its rating on Zealand Pharma to Neutral from Overweight, citing limited differentiation for petrelintide, noting the drug showed weight loss of approximately 9% placebo-adjusted at 42 weeks — similar to cagrilintide and meaningfully below Eli Lilly’s eloralintide.
The firm argued that the absence of a dose response provides no evidence that the weight-loss profile will improve in Phase 3, and that petrelintide could ultimately launch as a third-to-market monotherapy with limited differentiation — a stark reversal from the firm’s prior bull thesis.
Meanwhile, Deutsche Bank maintained a Hold rating with a DKK 300 price target, which analyst Emmanuel Papadakis noted represents approximately a 30% discount to the bank’s base-case net present value, reflecting challenging pipeline developments and long timelines to commercialization.
On the competitive front, Zealand faces a crowded obesity landscape. Eli Lilly is already ahead with eloralintide in Phase 3 with superior efficacy, while Novo Nordisk has also moved cagrilintide monotherapy into Phase 3 — two of the company’s most direct rivals in the amylin analog space.
The broader market environment offered no relief, with U.S. equities under broad pressure and the NASDAQ declining -4.2% and the S&P 500 falling -2.6%, creating a risk-off backdrop that disproportionately hit speculative biotech names.
The combination of a "sell the news" dynamic following the ADA data presentation, a fresh analyst downgrade questioning petrelintide’s competitive positioning, and a deteriorating macro environment converged to drive one of the stock’s steepest single-session declines in recent memory.
Zealand Pharma’s share price has been volatile over the past three months relative to the broader Danish market, with weekly volatility higher than 75% of Danish-listed stocks — a dynamic that amplified today’s sharp move toward the lower end of its 52-week range.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates ZELA alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if ZELA is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?